|Bid||33.00 x 900|
|Ask||52.00 x 2200|
|Day's range||34.70 - 39.11|
|52-week range||34.70 - 141.30|
|Beta (5Y monthly)||0.78|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2022 - 04 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||130.00|
SAN DIEGO (AP) _ Turning Point Therapeutics Inc. (TPTX) on Monday reported a loss of $47.4 million in its fourth quarter. The San Diego-based company said it had a loss of $1.02 per share. The results fell short of Wall Street expectations.
This oncology biotech is up over 450% since its April 2019 IPO. Are there still gains to come, or should investors turn away?
5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty